Chrisofos M - Search Results

1

The novel prostate cancer antigen 3 (PCA3) biomarker.

Bourdoumis A, Papatsoris AG, Chrisofos M, Efstathiou E, Skolarikos A, Deliveliotis C. Bourdoumis A, et al. Among authors: chrisofos m. Int Braz J Urol. 2010 Nov-Dec;36(6):665-8; discussion 669. doi: 10.1590/s1677-55382010000600003. Int Braz J Urol. 2010. PMID: 21176272 Free article. Review.

2

Diagnostic efficacy of transrectal ultrasound-guided biopsy of the prostatic fossa in patients with rising PSA following radical prostatectomy.

Deliveliotis C, Manousakas T, Chrisofos M, Skolarikos A, Delis A, Dimopoulos C. Deliveliotis C, et al. Among authors: chrisofos m. World J Urol. 2007 Jun;25(3):309-13. doi: 10.1007/s00345-007-0167-6. World J Urol. 2007. PMID: 17440730

3

Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer.

Mountzios I, Bournakis E, Efstathiou E, Varkaris A, Wen S, Chrisofos M, Deliveliotis C, Alamanis C, Anastasiou I, Constantinides C, Karadimou A, Tsiatas M, Papadimitriou C, Bamias A, Dimopoulos MA. Mountzios I, et al. Among authors: chrisofos m. Urology. 2011 Mar;77(3):682-7. doi: 10.1016/j.urology.2010.08.044. Epub 2011 Jan 22. Urology. 2011. PMID: 21256546

4

The role of the cell adhesion molecules (integrins/cadherins) in prostate cancer.

Drivalos A, Papatsoris AG, Chrisofos M, Efstathiou E, Dimopoulos MA. Drivalos A, et al. Among authors: chrisofos m. Int Braz J Urol. 2011 May-Jun;37(3):302-6. doi: 10.1590/s1677-55382011000300002. Int Braz J Urol. 2011. PMID: 21756376 Free article.

5

The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.

Bourdoumis A, Chrisofos M, Stasinou T, Christopoulos P, Mourmouris P, Kostakopoulos A, Deliveliotis C. Bourdoumis A, et al. Among authors: chrisofos m. Anticancer Res. 2015 May;35(5):3075-9. Anticancer Res. 2015. PMID: 25964598

6

Does the management of bladder perforation during transurethral resection of superficial bladder tumors predispose to extravesical tumor recurrence?

Skolarikos A, Chrisofos M, Ferakis N, Papatsoris A, Dellis A, Deliveliotis C. Skolarikos A, et al. Among authors: chrisofos m. J Urol. 2005 Jun;173(6):1908-11. doi: 10.1097/01.ju.0000158450.71497.ae. J Urol. 2005. PMID: 15879773

7

Is there a role for alpha1-blockers in treating double-J stent-related symptoms?

Deliveliotis C, Chrisofos M, Gougousis E, Papatsoris A, Dellis A, Varkarakis IM. Deliveliotis C, et al. Among authors: chrisofos m. Urology. 2006 Jan;67(1):35-9. doi: 10.1016/j.urology.2005.07.038. Urology. 2006. PMID: 16413328 Clinical Trial.

8

Finasteride effects on hypoxia and angiogenetic markers in benign prostatic hyperplasia.

Lekas AG, Lazaris AC, Chrisofos M, Papatsoris AG, Lappas D, Patsouris E, Deliveliotis C. Lekas AG, et al. Among authors: chrisofos m. Urology. 2006 Aug;68(2):436-41. doi: 10.1016/j.urology.2006.03.038. Urology. 2006. PMID: 16904480 Clinical Trial.

9

Use of nonsteroidal anti-inflammatory drugs after radical retropubic prostatectomy: a prospective, randomized trial.

Mazaris EM, Varkarakis I, Chrisofos M, Skolarikos A, Ioannidis K, Dellis A, Papatsoris A, Deliveliotis C. Mazaris EM, et al. Among authors: chrisofos m. Urology. 2008 Dec;72(6):1293-7. doi: 10.1016/j.urology.2007.12.039. Epub 2008 Mar 10. Urology. 2008. PMID: 18329071 Clinical Trial.

10

Upper urinary tract transitional cell carcinoma. A 10-year experience.

Papatsoris AG, Chrisofos M, Skolarikos A, Varkarakis I, Lekas A, Dellis A, Koritsiadis S, Deliveliotis C. Papatsoris AG, et al. Among authors: chrisofos m. Tumori. 2008 Jan-Feb;94(1):75-8. doi: 10.1177/030089160809400114. Tumori. 2008. PMID: 18468339

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

69 results

Search Page